Cargando…

Clinical Outcome of Low-Grade Myofibroblastic Sarcoma in Japan: A Multicenter Study from the Japanese Musculoskeletal Oncology Group

SIMPLE SUMMARY: Low-grade myofibroblastic sarcoma (LGMS) is one of the rarest sarcomas. We aimed to clarify the clinical outcomes of patients with LGMS. Twenty-two patients underwent surgical treatment for the primary tumor and two underwent radical radiotherapy (RT). The best overall response in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kito, Munehisa, Ae, Keisuke, Okamoto, Masanori, Endo, Makoto, Ikuta, Kunihiro, Takeuchi, Akihiko, Yasuda, Naohiro, Yasuda, Taketoshi, Imura, Yoshinori, Morii, Takeshi, Kikuta, Kazutaka, Kawamoto, Teruya, Nezu, Yutaka, Baba, Ichiro, Ohshika, Shusa, Uehara, Takeshi, Ueda, Takafumi, Takahashi, Jun, Kawano, Hirotaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137232/
https://www.ncbi.nlm.nih.gov/pubmed/37190242
http://dx.doi.org/10.3390/cancers15082314
_version_ 1785032411815346176
author Kito, Munehisa
Ae, Keisuke
Okamoto, Masanori
Endo, Makoto
Ikuta, Kunihiro
Takeuchi, Akihiko
Yasuda, Naohiro
Yasuda, Taketoshi
Imura, Yoshinori
Morii, Takeshi
Kikuta, Kazutaka
Kawamoto, Teruya
Nezu, Yutaka
Baba, Ichiro
Ohshika, Shusa
Uehara, Takeshi
Ueda, Takafumi
Takahashi, Jun
Kawano, Hirotaka
author_facet Kito, Munehisa
Ae, Keisuke
Okamoto, Masanori
Endo, Makoto
Ikuta, Kunihiro
Takeuchi, Akihiko
Yasuda, Naohiro
Yasuda, Taketoshi
Imura, Yoshinori
Morii, Takeshi
Kikuta, Kazutaka
Kawamoto, Teruya
Nezu, Yutaka
Baba, Ichiro
Ohshika, Shusa
Uehara, Takeshi
Ueda, Takafumi
Takahashi, Jun
Kawano, Hirotaka
author_sort Kito, Munehisa
collection PubMed
description SIMPLE SUMMARY: Low-grade myofibroblastic sarcoma (LGMS) is one of the rarest sarcomas. We aimed to clarify the clinical outcomes of patients with LGMS. Twenty-two patients underwent surgical treatment for the primary tumor and two underwent radical radiotherapy (RT). The best overall response in the two patients who underwent radical RT was one complete response and one partial response. Local relapse-free survival was 91.3% at 2 years and 75.4% at 5 years. Relapsed tumors were treated with surgery in two cases and radical RT in three cases. None of the patients experienced a second local relapse. Disease-specific survival was 100% at 5 years. Wide excision is recommended due to its tendency to local relapse. However, RT was considered a viable option in unresectable cases or in cases where surgery may cause significant functional impairment. ABSTRACT: This retrospective multicenter study aimed to analyze the clinical features and prognosis of 24 patients diagnosed with LGMS between 2002 and 2019 in the Japanese sarcoma network. Twenty-two cases were surgically treated and two cases were treated with radical radiotherapy (RT). The pathological margin was R0 in 14 cases, R1 in 7 cases, and R2 in 1 case. The best overall response in the two patients who underwent radical RT was one complete response and one partial response. Local relapse occurred in 20.8% of patients. Local relapse-free survival (LRFS) was 91.3% at 2 years and 75.4% at 5 years. In univariate analysis, tumors of 5 cm or more were significantly more likely to cause local relapse (p < 0.01). In terms of the treatment of relapsed tumors, surgery was performed in two cases and radical RT was performed in three cases. None of the patients experienced a second local relapse. Disease-specific survival was 100% at 5 years. A wide excision aimed at the microscopically R0 margin is considered the standard treatment for LGMS. However, RT may be a viable option in unresectable cases or in cases where surgery is expected to cause significant functional impairment.
format Online
Article
Text
id pubmed-10137232
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101372322023-04-28 Clinical Outcome of Low-Grade Myofibroblastic Sarcoma in Japan: A Multicenter Study from the Japanese Musculoskeletal Oncology Group Kito, Munehisa Ae, Keisuke Okamoto, Masanori Endo, Makoto Ikuta, Kunihiro Takeuchi, Akihiko Yasuda, Naohiro Yasuda, Taketoshi Imura, Yoshinori Morii, Takeshi Kikuta, Kazutaka Kawamoto, Teruya Nezu, Yutaka Baba, Ichiro Ohshika, Shusa Uehara, Takeshi Ueda, Takafumi Takahashi, Jun Kawano, Hirotaka Cancers (Basel) Article SIMPLE SUMMARY: Low-grade myofibroblastic sarcoma (LGMS) is one of the rarest sarcomas. We aimed to clarify the clinical outcomes of patients with LGMS. Twenty-two patients underwent surgical treatment for the primary tumor and two underwent radical radiotherapy (RT). The best overall response in the two patients who underwent radical RT was one complete response and one partial response. Local relapse-free survival was 91.3% at 2 years and 75.4% at 5 years. Relapsed tumors were treated with surgery in two cases and radical RT in three cases. None of the patients experienced a second local relapse. Disease-specific survival was 100% at 5 years. Wide excision is recommended due to its tendency to local relapse. However, RT was considered a viable option in unresectable cases or in cases where surgery may cause significant functional impairment. ABSTRACT: This retrospective multicenter study aimed to analyze the clinical features and prognosis of 24 patients diagnosed with LGMS between 2002 and 2019 in the Japanese sarcoma network. Twenty-two cases were surgically treated and two cases were treated with radical radiotherapy (RT). The pathological margin was R0 in 14 cases, R1 in 7 cases, and R2 in 1 case. The best overall response in the two patients who underwent radical RT was one complete response and one partial response. Local relapse occurred in 20.8% of patients. Local relapse-free survival (LRFS) was 91.3% at 2 years and 75.4% at 5 years. In univariate analysis, tumors of 5 cm or more were significantly more likely to cause local relapse (p < 0.01). In terms of the treatment of relapsed tumors, surgery was performed in two cases and radical RT was performed in three cases. None of the patients experienced a second local relapse. Disease-specific survival was 100% at 5 years. A wide excision aimed at the microscopically R0 margin is considered the standard treatment for LGMS. However, RT may be a viable option in unresectable cases or in cases where surgery is expected to cause significant functional impairment. MDPI 2023-04-15 /pmc/articles/PMC10137232/ /pubmed/37190242 http://dx.doi.org/10.3390/cancers15082314 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kito, Munehisa
Ae, Keisuke
Okamoto, Masanori
Endo, Makoto
Ikuta, Kunihiro
Takeuchi, Akihiko
Yasuda, Naohiro
Yasuda, Taketoshi
Imura, Yoshinori
Morii, Takeshi
Kikuta, Kazutaka
Kawamoto, Teruya
Nezu, Yutaka
Baba, Ichiro
Ohshika, Shusa
Uehara, Takeshi
Ueda, Takafumi
Takahashi, Jun
Kawano, Hirotaka
Clinical Outcome of Low-Grade Myofibroblastic Sarcoma in Japan: A Multicenter Study from the Japanese Musculoskeletal Oncology Group
title Clinical Outcome of Low-Grade Myofibroblastic Sarcoma in Japan: A Multicenter Study from the Japanese Musculoskeletal Oncology Group
title_full Clinical Outcome of Low-Grade Myofibroblastic Sarcoma in Japan: A Multicenter Study from the Japanese Musculoskeletal Oncology Group
title_fullStr Clinical Outcome of Low-Grade Myofibroblastic Sarcoma in Japan: A Multicenter Study from the Japanese Musculoskeletal Oncology Group
title_full_unstemmed Clinical Outcome of Low-Grade Myofibroblastic Sarcoma in Japan: A Multicenter Study from the Japanese Musculoskeletal Oncology Group
title_short Clinical Outcome of Low-Grade Myofibroblastic Sarcoma in Japan: A Multicenter Study from the Japanese Musculoskeletal Oncology Group
title_sort clinical outcome of low-grade myofibroblastic sarcoma in japan: a multicenter study from the japanese musculoskeletal oncology group
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137232/
https://www.ncbi.nlm.nih.gov/pubmed/37190242
http://dx.doi.org/10.3390/cancers15082314
work_keys_str_mv AT kitomunehisa clinicaloutcomeoflowgrademyofibroblasticsarcomainjapanamulticenterstudyfromthejapanesemusculoskeletaloncologygroup
AT aekeisuke clinicaloutcomeoflowgrademyofibroblasticsarcomainjapanamulticenterstudyfromthejapanesemusculoskeletaloncologygroup
AT okamotomasanori clinicaloutcomeoflowgrademyofibroblasticsarcomainjapanamulticenterstudyfromthejapanesemusculoskeletaloncologygroup
AT endomakoto clinicaloutcomeoflowgrademyofibroblasticsarcomainjapanamulticenterstudyfromthejapanesemusculoskeletaloncologygroup
AT ikutakunihiro clinicaloutcomeoflowgrademyofibroblasticsarcomainjapanamulticenterstudyfromthejapanesemusculoskeletaloncologygroup
AT takeuchiakihiko clinicaloutcomeoflowgrademyofibroblasticsarcomainjapanamulticenterstudyfromthejapanesemusculoskeletaloncologygroup
AT yasudanaohiro clinicaloutcomeoflowgrademyofibroblasticsarcomainjapanamulticenterstudyfromthejapanesemusculoskeletaloncologygroup
AT yasudataketoshi clinicaloutcomeoflowgrademyofibroblasticsarcomainjapanamulticenterstudyfromthejapanesemusculoskeletaloncologygroup
AT imurayoshinori clinicaloutcomeoflowgrademyofibroblasticsarcomainjapanamulticenterstudyfromthejapanesemusculoskeletaloncologygroup
AT moriitakeshi clinicaloutcomeoflowgrademyofibroblasticsarcomainjapanamulticenterstudyfromthejapanesemusculoskeletaloncologygroup
AT kikutakazutaka clinicaloutcomeoflowgrademyofibroblasticsarcomainjapanamulticenterstudyfromthejapanesemusculoskeletaloncologygroup
AT kawamototeruya clinicaloutcomeoflowgrademyofibroblasticsarcomainjapanamulticenterstudyfromthejapanesemusculoskeletaloncologygroup
AT nezuyutaka clinicaloutcomeoflowgrademyofibroblasticsarcomainjapanamulticenterstudyfromthejapanesemusculoskeletaloncologygroup
AT babaichiro clinicaloutcomeoflowgrademyofibroblasticsarcomainjapanamulticenterstudyfromthejapanesemusculoskeletaloncologygroup
AT ohshikashusa clinicaloutcomeoflowgrademyofibroblasticsarcomainjapanamulticenterstudyfromthejapanesemusculoskeletaloncologygroup
AT ueharatakeshi clinicaloutcomeoflowgrademyofibroblasticsarcomainjapanamulticenterstudyfromthejapanesemusculoskeletaloncologygroup
AT uedatakafumi clinicaloutcomeoflowgrademyofibroblasticsarcomainjapanamulticenterstudyfromthejapanesemusculoskeletaloncologygroup
AT takahashijun clinicaloutcomeoflowgrademyofibroblasticsarcomainjapanamulticenterstudyfromthejapanesemusculoskeletaloncologygroup
AT kawanohirotaka clinicaloutcomeoflowgrademyofibroblasticsarcomainjapanamulticenterstudyfromthejapanesemusculoskeletaloncologygroup